tradingkey.logo

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

ReutersMar 25, 2025 11:33 AM

- Scholar Rock Holding Corp SRRK.O:

  • FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHY

  • SCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025

  • SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI